Shafiei Irannejad, V and Soraya, H and M.L. Janssen, P and Abbaszadeh, S (2021) Memantine and its benefits for cancer, cardiovascular and neurological disorders. European Journal of Pharmacology, 910. pp. 1-11.
|
Text
2384.pdf Download (1MB) | Preview |
Abstract
Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that was initially indicated for the treatment of moderate to severe Alzheimer’s disease. It is now also considered for a variety of other pathologies in which activation of NMDA receptors apparently contributes to the pathogenesis and progression of disease. In addition to the central nervous system (CNS), NMDA receptors can be found in non-neuronal cells and tissues that recently have become an interesting research focus. Some studies have shown that glutamate signaling plays a role in cell transformation and cancer progression. In addition, these receptors may play a role in cardiovascular disorders. In this review, we focus on the most recent findings for memantine with respect to its pharmacological effects in a range of diseases, including inflammatory disorders, cardiovascular diseases, cancer, neuropathy, as well as retinopathy
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Memantine NMDA receptors Cancer Neuropathy Retinopathy Cardiovascular diseases Inflammation |
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Unnamed user with email gholipour.s@umsu.ac.ir |
| Date Deposited: | 12 Oct 2021 05:59 |
| Last Modified: | 12 Oct 2021 05:59 |
| URI: | http://eprints.umsu.ac.ir/id/eprint/6318 |
Actions (login required)
 |
View Item |
